Compare Eli Lilly And Co (LLY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Otis Worldwide Corp — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: Eli Lilly And Co is far larger — about 41.3× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Otis Worldwide Corp for 66 Days on average.
| LLY | OTIS | |
|---|---|---|
Market Cap | $1.04T | $25.17B |
Volume | 3,064,878 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $1.28K | $93.62 |
52-Week Low | $799.57 | $64.05 |
Typical Hold Time | 93 Days | 66 Days |
Enterprise Value | $1.09T | $33.20B |
Dividend Yield | 0.59% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Otis Worldwide trades at $66.11, near its 52-week low, with a bearish technical signal and recent earnings misses in Q4 2025, Q1 2026, and Q2 2026. The company maintains stable revenue around $14.4B in 2025 but faces margin pressure, with net income margin at 10.17%. Analyst consensus is split between Buy and Hold, with a price target of $87.00, indicating potential upside. Recent news highlights CEO succession plans and challenges in China demand.
The outlook for Otis hinges on service margin recovery and China market stabilization. Investment opportunities include its dominant market position and durable cash flow from service contracts, but risks involve persistent cost pressures, high debt levels, and weak equipment demand. Wall Street remains cautiously optimistic given the valuation discount to targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
